Ipsen Provides Update On Phase III CONTACT-01 Trial Evaluating Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Non-small Cell Lung Cancer Previously Treated With Immunotherapy and Chemotherapy

The trial did not meet its primary endpoint of overall survival (OS) The safety profile of the combination of cabozantinib and atezolizumab was consistent with the known safety profiles for

Related Keywords

Saclay ,France General ,France ,Japan ,Shanghai ,China ,United States ,Paris ,Cambridge ,Cambridgeshire ,United Kingdom ,American ,Howard Mayer ,Ioana Piscociu ,Ipsen Euronext ,Head Of Research ,European Union ,Takeda Pharmaceutical Company Limited ,Executive Vice President ,Both Ipsen ,Rare Disease ,With Specialty Care ,Sponsored Leveli American Depositary Receipt ,Forward Looking Statements ,French Autorit ,Des March ,Registration Document ,Investor Relations ,Franchise Communicationsoncology ,Relations Manager ,Media Relations ,Lipsen ,Rovides ,Update ,Hase ,Contact ,Trial ,Valuating ,Cabozantinib ,Combination ,Ith ,Atezolizumab ,Patients ,Metastatic ,Mall ,Fell ,Young ,Dancer ,Reviously ,Reated ,Immunotherapy ,Chemothe ,